News

Discover which gynecologic cancer abstracts experts believe may affect evolving treatment paradigms and patient care discussions at ASCO 2026.

Researchers from Roswell Park led key studies presented at the 2026 AUA Annual Meeting.

A supplemental BLA for nogapendekin alfa inbakicept plus BCG for BCG-unresponsive NMIBC with papillary-only disease is under review by the FDA.

The FDA has granted fast track designation to suplexa in MSI-H CRC.

The FDA granted orphan drug designation to CLN-049 for relapsed or refractory acute myeloid leukemia based on data from early-phase studies.

Researchers found that macrophages are associated with response to chemotherapy before treatment in triple-negative breast cancer.

Suchitra Sundaram, MD, discusses the assortment of therapies available in chronic lymphocytic leukemia and frontline approaches.

Matthew Galsky, MD, discusses the present and future treatment landscape of MIBC during Bladder Cancer Awareness Month.

Sevabertinib has received priority review designation from the FDA in locally advanced or metastatic, HER2 TKD–mutant NSCLC.

OncLive announced the 2026 Giants of Cancer Care winners.

Ibrutinib/Rituximab Preserves QOL vs FCR in Previously Untreated CLL

In an indirect comparison, NAI+BCG showed numerically higher, significantly longer responses and a trend toward greater bladder preservation vs nadofaragene.

Enzalutamide plus radium-223 demonstrated no early survival advantage but an 80% death risk reduction for long-term survivors in mCRPC at over 60 months.

Rucaparib showed a manageable and consistent safety profile in patients with BRCA-mutated prostate cancer.

The FDA has issued a ‘safe to proceed’ for an application for a novel CAR T-cell therapy in CD94-positive lymphomas.

Second-line annamycin plus cytarabine injections demonstrated promising responses in patients with relapsed or refractory acute myeloid leukemia.

No new safety signals were identified, and imAEs were predominantly low-grade and consistent with the known durvalumab safety profile.

In case you missed any, check out our recap of the episodes of OncLive On Air that aired in April 2026.

The PD-1/antiangiogenic combination yielded a 24% ORR and 28-month median PFS, surpassing prior monotherapy benchmarks in refractory chordoma.

Adding lutetium Lu 177 vipivotide tetraxetan to ADT and ARPI deepened PSA responses and reduced the risk of PSA progression by 58% in patients with mHSPC.

Talazoparib plus enzalutamide data show rPFS correlates moderate-to-strongly with OS in first-line mCRPC across biomarker-defined subgroups.

Enzalutamide plus leuprolide produced a median treatment suspension of 17 months vs 11.5 months with leuprolide alone in biochemically recurrent prostate cancer.

The top 5 OncLive TV videos of the week cover insights in breast cancer, acute myeloid leukemia, bladder cancer, multiple myeloma, and melanoma.

The FDA approved T-DXd in early HER2+ breast cancer, adjuvant atezolizumab in MRD+ MIBC, and more.

Two doses of intravesical mitomycin-C administered before TURBT produced a 77% reduction in the risk of recurrence or death vs TURBT alone in NMIBC.